Peer Review History
| Original SubmissionJune 17, 2022 |
|---|
|
PONE-D-22-17433Estimating the unseen emergence of COVID-19 in the US PLOS ONE Dear Dr. Javan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Nov 19 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Sung-mok Jung Academic Editor PLOS ONE Journal Requirements When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, all author-generated code must be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse. 3. We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright. We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission: a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license. We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.” Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].” b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only. The following resources for replacing copyrighted map figures may be helpful: USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/ The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/ Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/ Landsat: http://landsat.visibleearth.nasa.gov/ USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/# Natural Earth (public domain): http://www.naturalearthdata.com/ Additional Editor Comments: I agree with the authors that early risk assessment is essential, and the model developed for the Zika virus can aid in determining the probability of undetected transmissions. However, as both reviewers mentioned, I also have concerns on the model validation and assumptions used in the model (including parameters). Thus, I would be great if authors could response to those comments and add additional analyses to validate the proposed model by comparing model estimates with the empirically observed data. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors present results from an SEIR model developed for Zika that was adapted to SARS-CoV-2 to determine risk of an undetected outbreak by county given x number of reported cases in that county. The author summary suggests that the model was developed to support local decision makers during the early phase of the pandemic, but there is no discussion of this point. I think that if the authors are planning to frame their article as developed to support local decision-making, they need to spend a substantially more amount of text discussing/analyzing this. Was the model used? Was any validation of the model done? How long did it take for counties to reach 1,000 cumulative cases (Fig 3)? How do the authors define an “epidemic” for their purpose of evaluating epidemic risk? (Especially with regard to interpretation of Figure 1) While I appreciate the value of a simple model, I do believe the framing of the paper requires more evaluation/discussion of the practical implications of the model. If the intent of the authors is not to do that, it would be ideal to reframe the article to emphasize potential for future use of the model rather than utility of the model during the early phase of the COVID-19 pandemic (or some other reframing). Minor notes: “Undetected” epidemic is a phrase more commonly used to describe what the authors assess rather than “unseen” epidemic, which has more of a literary feel. The description of COVID-19 “waves” in the first paragraph of the results seems a non sequitur from the introduction as the focus of this is the earliest phase of the pandemic before it was truly grasped that there would be so many waves. Line 48: the long-form name for COVID-19 is “coronavirus disease 2019”—if the authors wish/prefer to use “novel coronavirus” as a nod to the original name for the disease, it would be prudent to do so separately from establishment of the acronym. Line 179: Please define/explain the use of the term boxcars. Fig 3: Please define total cases and how this is different from reported cases. Reviewer #2: In this manuscript the authors repurposed a model that was previously used to study the spread of the Zika Virus to estimate the probability of unseen transmission. The model uses a stochastic SEIR branching process to simulate the outbreak until April 2020. The authors find that counties that have confirmed one case have a 50% probability of an epidemic. The authors did a lot of work reconstructing the early stage of the epidemic for each county in the US. Understanding the early phase of an emerging epidemic is crucial and I applaud and thank the authors for their hard work providing situational awareness to both public health departments and the public. With the current version of the paper I have a few issues and concerns about the model assumptions and I believe there is a lack of validation. I have broken down my comments into Major and Minor issues below. Major issues -Model assumptions: From my understanding of the paper, it says that all counties have the same Re which is either 1.1, 1.5, or 3 and that is held constant throughout the entire stochastic process. If this is the case, I do not believe this is appropriate. In addition, I do not think it is true that all counties had similar transmission rates. I agree with the authors that in early March the Re was most likely closer to 3 due to the lack of interventions. However, it changed when places started social distancing/ working from home/ only opening essential services. There are multiple data sources out there reporting the Rt and changes in mobility (some at the county level) that could be incorporated to adjust for this. I know it is a lot of work but including this heterogeneity could change the results. I am also concerned about the estimate for the Latent period, this value (1.25 days) is one of the smaller values I have seen for the early estimates of this parameter. Most of the values I have read are between 2-7 days. -Model calibration: Can the authors also confirm the calibration procedure for each individual county? From what I read, in order to get the variation in the timing of individual counties, stochastic runs are shifted to match the case data. However, I’m not entirely sure exactly how this is done. Do you choose one date (March 16) or a group of dates? I guess I’m not sure what the “fitting window” is and how the model is mapped to actual dates because the model doesn’t use information on importations, the timing of the start of the outbreak… etc. -Validation: This paper is missing statistical validation of the model estimates vs. observational data. The model is currently validated by looking at whether case counts increased in the following week. In Figure 4, the model estimates are overlapped with the values using reported cases. However, I think a more quantitative way of validating the model against the surveillance data should be used. Possibly some correlation measure. Another type of validation measure that could be useful is based on the timing of community transmission at the county level (answering “when” did counties have widespread transmission and was it similar to what we observed with reported cases). So looking at the temporal evolution of the early phase. I also think that this paper is missing a discussion on how this analysis aligns with the literature. There has been a lot of work on the early phase of the epidemic using phylogenetic analysis, retrospective samples, waste water surveillance, and other epidemic modeling approaches within the US (not much at the county level). While there isn’t a single, comprehensive paper to compare this work to, it would contribute to the validation of the model and deepen the discussion. Minor Issue: -Language of unseen transmission: As of now, the paper uses many different words and phrases to describe an “unseen epidemic” and how to estimate it such as: epidemic risk, unseen transmission, widespread transmission, sustained community transmission, and outbreaks that spread widely. It would useful and helpful to the reader to use a common terminology that is defined explicitly in the main paper. From what I read “epidemic risk” is the most well defined, but I’ll leave that up to the authors to decide what works best. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Estimating the undetected emergence of COVID-19 in the US PONE-D-22-17433R1 Dear Dr. Javan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Sung-mok Jung Academic Editor PLOS ONE Additional Editor Comments (optional): I believe all of the comments from reviewers have been well addressed in the revised manuscript. I appreciate authors' effort and congratulations on the publication. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No ********** |
| Formally Accepted |
|
PONE-D-22-17433R1 Estimating the undetected emergence of COVID-19 in the US Dear Dr. Javan: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Sung-mok Jung Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .